NYSE:HAE - Haemonetics Stock Price, Price Target & More

$75.75 +0.45 (+0.60 %)
(As of 04/19/2018 07:30 AM ET)
Previous Close$75.30
Today's Range$75.10 - $76.27
52-Week Range$38.47 - $76.27
Volume323,200 shs
Average Volume472,465 shs
Market Capitalization$4.02 billion
P/E Ratio41.37
Dividend YieldN/A
Beta0.89

About Haemonetics (NYSE:HAE)

Haemonetics logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:HAE
CUSIP40502410
Phone781-848-7100

Debt

Debt-to-Equity Ratio0.14%
Current Ratio1.82%
Quick Ratio1.33%

Price-To-Earnings

Trailing P/E Ratio41.37
Forward P/E Ratio40.73
P/E Growth3.28

Sales & Book Value

Annual Sales$886.12 million
Price / Sales4.57
Cash Flow$3.2693 per share
Price / Cash23.17
Book Value$14.22 per share
Price / Book5.33

Profitability

EPS (Most Recent Fiscal Year)$1.53
Net Income$-26,260,000.00
Net Margins-1.94%
Return on Equity12.39%
Return on Assets7.66%

Miscellaneous

Employees3,107
Outstanding Shares53,450,000

How to Become a New Pot Stock Millionaire

Haemonetics (NYSE:HAE) Frequently Asked Questions

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

How will Haemonetics' stock buyback program work?

Haemonetics announced that its board has approved a share buyback program on Tuesday, February 6th 2018, which allows the company to buyback $260,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company's board of directors believes its stock is undervalued.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) announced its quarterly earnings data on Tuesday, February, 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.18. The medical instruments supplier earned $234.04 million during the quarter, compared to the consensus estimate of $227.79 million. Haemonetics had a negative net margin of 1.94% and a positive return on equity of 12.39%. The firm's revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.43 EPS. View Haemonetics' Earnings History.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Haemonetics.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY18 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of $1.80-1.90 for the period, compared to the Thomson Reuters consensus estimate of $1.70.

What price target have analysts set for HAE?

6 analysts have issued 1 year price targets for Haemonetics' stock. Their forecasts range from $50.00 to $80.00. On average, they expect Haemonetics' share price to reach $70.00 in the next year. View Analyst Ratings for Haemonetics.

Who are some of Haemonetics' key competitors?

Who are Haemonetics' key executives?

Haemonetics' management team includes the folowing people:
  • Christopher Simon, President, Chief Executive Officer, Director (Age 53)
  • William P. Burke, Chief Financial Officer, Executive Vice President (Age 49)
  • David J. Wilson, President - Plasma Business Unit
  • Michelle Basil, Executive Vice President, General Counsel (Age 45)
  • Neil Ryding, Executive Vice President, Global Operations (Age 56)
  • Richard J. Meelia, Non-Executive Independent Chairman of the Board (Age 68)
  • Robert E. Abernathy, Director (Age 63)
  • Ellen M. Zane, Director (Age 66)
  • Catherine M. Burzik, Independent Director (Age 67)
  • Charles J. Dockendorff, Independent Director (Age 63)

Has Haemonetics been receiving favorable news coverage?

Media coverage about HAE stock has been trending very positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Haemonetics earned a daily sentiment score of 0.53 on Accern's scale. They also assigned media headlines about the medical instruments supplier an impact score of 45.22 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $75.75.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $4.02 billion and generates $886.12 million in revenue each year. The medical instruments supplier earns $-26,260,000.00 in net income (profit) each year or $1.53 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.

How can I contact Haemonetics?

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


MarketBeat Community Rating for Haemonetics (HAE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  435
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Haemonetics (NYSE:HAE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Haemonetics in the last 12 months. Their average twelve-month price target is $70.00, suggesting that the stock has a possible downside of 7.59%. The high price target for HAE is $80.00 and the low price target for HAE is $50.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $70.00$70.00$56.60$44.60
Price Target Upside: 7.59% downside2.13% upside9.73% downside3.84% downside

Haemonetics (NYSE:HAE) Consensus Price Target History

Price Target History for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/7/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$74.00 -> $77.00HighView Rating Details
2/7/2018Barrington ResearchReiterated RatingOutperform -> Outperform$57.00 -> $71.00HighView Rating Details
2/7/2018JMP SecuritiesReiterated RatingOutperform$72.00HighView Rating Details
2/7/2018Jefferies GroupReiterated RatingBuy$80.00HighView Rating Details
1/2/2018Raymond JamesUpgradeUnderperform -> Market PerformHighView Rating Details
11/8/2017Craig HallumReiterated RatingHold$40.00 -> $50.00N/AView Rating Details
11/7/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
11/7/2016BenchmarkBoost Price TargetHold$32.00 -> $34.00N/AView Rating Details
10/14/2016Off Wall StreetInitiated CoverageSell$24.00N/AView Rating Details
9/20/2016CJS SecuritiesDowngradeMarket Outperform -> Market Perform$35.00N/AView Rating Details
8/15/2016SidotiDowngradeBuy -> Neutral$39.00N/AView Rating Details
5/16/2016Goldman SachsUpgradeSell -> Neutral$29.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Haemonetics (NYSE:HAE) Earnings History and Estimates Chart

Earnings by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) Earnings Estimates

2018 EPS Consensus Estimate: $1.58
2019 EPS Consensus Estimate: $2.08
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.25$0.37$0.30
Q2 20183$0.38$0.47$0.44
Q3 20183$0.41$0.45$0.43
Q4 20182$0.40$0.43$0.42
Q1 20193$0.41$0.46$0.44
Q2 20193$0.51$0.56$0.54
Q3 20193$0.54$0.63$0.58
Q4 20193$0.49$0.54$0.52

Haemonetics (NYSE HAE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$0.43N/AView Earnings Details
2/6/2018Q3 2018$0.44$0.62$227.79 million$234.04 millionViewListenView Earnings Details
11/7/2017Q2 2018$0.41$0.48$219.12 million$225.40 millionViewN/AView Earnings Details
8/7/2017Q1 2018$0.31$0.33$211.29 million$211.00 millionViewListenView Earnings Details
5/8/2017Q4 2017$0.37$0.39$215.06 million$228.10 millionViewListenView Earnings Details
2/6/2017Q317$0.40$0.43$220.00 million$227.80 millionViewListenView Earnings Details
11/7/2016Q217$0.35$0.46$210.72 million$220.30 millionViewListenView Earnings Details
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.51$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.51$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.45$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.35$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
11/1/2010Q2 2011$0.38$0.40ViewN/AView Earnings Details
8/2/2010Q1 2011$0.36$0.37ViewN/AView Earnings Details
5/4/2010Q4 2010$0.38$0.38ViewN/AView Earnings Details
2/1/2010Q3 2010$0.36$0.35ViewN/AView Earnings Details
11/2/2009Q2 2010$0.33$0.34ViewN/AView Earnings Details
8/3/2009Q1 2010$0.33$0.35ViewN/AView Earnings Details
5/4/2009Q4 2009$0.32$0.32ViewN/AView Earnings Details
2/2/2009Q3 2009$0.31$0.32ViewN/AView Earnings Details
10/27/2008Q2 2009$0.28$0.29ViewN/AView Earnings Details
8/1/2008Q1 2009$0.28$0.29ViewN/AView Earnings Details
5/1/2008Q4 2008$0.29$0.29ViewN/AView Earnings Details
1/31/2008Q3 2008$0.27$0.29ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Haemonetics (NYSE:HAE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Haemonetics (NYSE HAE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Insider Trading History for Haemonetics (NYSE:HAE)
Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Haemonetics (NYSE HAE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/6/2018Dan GoldsteinVPSell518$54.65$28,308.704,002View SEC Filing  
3/6/2018Jacqueline ScanlanSVPSell114$72.23$8,234.22View SEC Filing  
3/6/2018Michelle L. BasilEVPSell389$72.23$28,097.47View SEC Filing  
1/2/2018Mark W KrollDirectorSell7,118$63.00$448,434.0033,881View SEC Filing  
12/1/2017Pedro P GranadilloDirectorSell7,118$57.06$406,153.0831,663View SEC Filing  
11/16/2017Ronald G GelbmanDirectorSell5,440$56.69$308,393.60View SEC Filing  
11/14/2017Willaim P BurkeCFOSell13,193$54.04$712,949.7227,227View SEC Filing  
11/13/2017Dan GoldsteinCAOSell4,691$54.93$257,676.633,747View SEC Filing  
11/10/2017Susan Bartlett FooteDirectorSell16,926$54.19$917,219.9427,313View SEC Filing  
5/22/2017Ronald MerrimanDirectorSell17,471$40.33$704,605.4324,925View SEC Filing  
12/12/2016Ronald G GelbmanDirectorSell5,683$40.30$229,024.9049,688View SEC Filing  
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.1822,088View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.7212,010View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.6845,350View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.1420,096View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.6120,464View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35147,040View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95147,040View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.9838,188View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.449,939View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.1814,901View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00130,307View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.0028,950View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.2614,901View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00130,307View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.0039,173View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00130,307View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.0016,905View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.8025,166View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00130,307View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.2216,905View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.0016,905View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00130,307View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.0016,905View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.6616,905View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00130,307View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.0010,987View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.0011,337View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.0011,337View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00115,798View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Haemonetics (NYSE HAE) News Headlines

Source:
DateHeadline
Teleflex (TFX) versus Haemonetics (HAE) Critical ContrastTeleflex (TFX) versus Haemonetics (HAE) Critical Contrast
www.americanbankingnews.com - April 18 at 1:20 AM
BidaskClub Downgrades Haemonetics (HAE) to Strong SellBidaskClub Downgrades Haemonetics (HAE) to Strong Sell
www.americanbankingnews.com - April 15 at 1:17 PM
Haemonetics (HAE) Lifted to Sell at BidaskClubHaemonetics (HAE) Lifted to Sell at BidaskClub
www.americanbankingnews.com - April 12 at 6:15 PM
$224.57 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter$224.57 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter
www.americanbankingnews.com - April 12 at 4:37 AM
Haemonetics Co. (HAE) Receives Average Recommendation of "Hold" from AnalystsHaemonetics Co. (HAE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 12 at 1:29 AM
Haemonetics (HAE) Lifted to "Buy" at Zacks Investment ResearchHaemonetics (HAE) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:27 PM
Haemonetics Rides High on Plasma, Blood Center Remains WeakHaemonetics Rides High on Plasma, Blood Center Remains Weak
finance.yahoo.com - April 11 at 4:28 PM
Haemonetics (HAE) Lowered to "Sell" at Zacks Investment ResearchHaemonetics (HAE) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 10:25 AM
Insider Selling: Haemonetics Co. (HAE) VP Sells 518 Shares of StockInsider Selling: Haemonetics Co. (HAE) VP Sells 518 Shares of Stock
www.americanbankingnews.com - April 10 at 7:31 PM
Haemonetics Sets Date for Publishing Fourth Quarter Fiscal 2018 Results: May 8, 2018Haemonetics Sets Date for Publishing Fourth Quarter Fiscal 2018 Results: May 8, 2018
finance.yahoo.com - April 10 at 9:54 AM
Zacks: Analysts Anticipate Haemonetics Co. (HAE) Will Announce Earnings of $0.43 Per ShareZacks: Analysts Anticipate Haemonetics Co. (HAE) Will Announce Earnings of $0.43 Per Share
www.americanbankingnews.com - April 10 at 5:24 AM
Haemonetics (HAE) Upgraded to Strong-Buy by ValuEngineHaemonetics (HAE) Upgraded to Strong-Buy by ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM
Haemonetics' Plasma Tool Enhancement Gets 510(K) ClearanceHaemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
finance.yahoo.com - April 2 at 4:29 PM
Haemonetics Plasma Tool Enhancement Gets 510(K) ClearanceHaemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
feeds.benzinga.com - April 2 at 1:52 PM
Barrington Research Increases Haemonetics (HAE) Price Target to $57.00Barrington Research Increases Haemonetics (HAE) Price Target to $57.00
www.americanbankingnews.com - April 1 at 9:40 AM
Haemonetics (HAE) PT Raised to $51.00 at Morgan StanleyHaemonetics (HAE) PT Raised to $51.00 at Morgan Stanley
www.americanbankingnews.com - March 31 at 5:28 PM
Haemonetics (HAE) Raised to Overweight at Morgan StanleyHaemonetics (HAE) Raised to Overweight at Morgan Stanley
www.americanbankingnews.com - March 31 at 12:54 PM
Head to Head Analysis: Sientra (SIEN) versus Haemonetics (HAE)Head to Head Analysis: Sientra (SIEN) versus Haemonetics (HAE)
www.americanbankingnews.com - March 29 at 10:19 AM
Haemonetics Announces Regulatory Clearances of NexSys PCS™ Enhanced Software ...Haemonetics Announces Regulatory Clearances of NexSys PCS™ Enhanced Software ...
www.prnewswire.com - March 29 at 9:53 AM
Haemonetics Announces Regulatory Clearances of NexSys PCS™ Enhanced Software with YES™ TechnologyHaemonetics Announces Regulatory Clearances of NexSys PCS™ Enhanced Software with YES™ Technology
finance.yahoo.com - March 28 at 9:44 AM
Why Should You Add Haemonetics (HAE) to Your Portfolio Now?Why Should You Add Haemonetics (HAE) to Your Portfolio Now?
finance.yahoo.com - March 26 at 4:19 PM
Haemonetics (HAE) Stock Rating Reaffirmed by Jefferies GroupHaemonetics (HAE) Stock Rating Reaffirmed by Jefferies Group
www.americanbankingnews.com - March 25 at 7:44 AM
Zacks: Analysts Expect Haemonetics Co. (HAE) to Announce $0.43 Earnings Per ShareZacks: Analysts Expect Haemonetics Co. (HAE) to Announce $0.43 Earnings Per Share
www.americanbankingnews.com - March 24 at 5:24 AM
It Is Still Not Too Late To Pick Up Haemonetics In CY 2018It Is Still Not Too Late To Pick Up Haemonetics In CY 2018
seekingalpha.com - March 21 at 10:40 AM
The Hospital Business Remains 1of HAE’s Key Growth DriversThe Hospital Business Remains 1of HAE’s Key Growth Drivers
finance.yahoo.com - March 21 at 10:40 AM
HAE Focuses on Revitalizing Cell Salvage Business in Fiscal 2018HAE Focuses on Revitalizing Cell Salvage Business in Fiscal 2018
finance.yahoo.com - March 21 at 10:40 AM
Plasma Remains an Attractive Business for HAEPlasma Remains an Attractive Business for HAE
finance.yahoo.com - March 20 at 4:19 PM
Haemonetics Co. (HAE) to Post Q1 2019 Earnings of $0.41 Per Share, William Blair ForecastsHaemonetics Co. (HAE) to Post Q1 2019 Earnings of $0.41 Per Share, William Blair Forecasts
www.americanbankingnews.com - March 20 at 11:12 AM
Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018
finance.yahoo.com - March 20 at 9:41 AM
Cerus (CERS) Looks Good: Stock Adds 9.5% in SessionCerus (CERS) Looks Good: Stock Adds 9.5% in Session
finance.yahoo.com - March 19 at 9:41 AM
Haemonetics Co. (HAE) Receives Average Recommendation of "Buy" from AnalystsHaemonetics Co. (HAE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 18 at 1:36 AM
Analyzing K2M Group (KTWO) and Haemonetics (HAE)Analyzing K2M Group (KTWO) and Haemonetics (HAE)
www.americanbankingnews.com - March 11 at 1:22 AM
3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax3 Stocks to Gain as Trump Pulls Plug on Infamous MedTech Tax
finance.yahoo.com - March 9 at 5:27 PM
Haemonetics Co. (HAE) Expected to Announce Quarterly Sales of $223.09 MillionHaemonetics Co. (HAE) Expected to Announce Quarterly Sales of $223.09 Million
www.americanbankingnews.com - March 9 at 2:41 PM
Haemonetics Co. (HAE) EVP Sells $28,097.47 in StockHaemonetics Co. (HAE) EVP Sells $28,097.47 in Stock
www.americanbankingnews.com - March 8 at 7:27 PM
Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?
finance.yahoo.com - March 8 at 5:19 PM
$0.43 Earnings Per Share Expected for Haemonetics Co. (HAE) This Quarter$0.43 Earnings Per Share Expected for Haemonetics Co. (HAE) This Quarter
www.americanbankingnews.com - March 7 at 1:16 AM
Schroder Investment Management Group Cuts Holdings in Haemonetics Co. (HAE)Schroder Investment Management Group Cuts Holdings in Haemonetics Co. (HAE)
www.americanbankingnews.com - March 6 at 9:48 AM
Rhumbline Advisers Has $7.14 Million Stake in Haemonetics Co. (HAE)Rhumbline Advisers Has $7.14 Million Stake in Haemonetics Co. (HAE)
www.americanbankingnews.com - March 6 at 9:02 AM
BlackRock Inc. Raises Position in Haemonetics Co. (HAE)BlackRock Inc. Raises Position in Haemonetics Co. (HAE)
www.americanbankingnews.com - March 6 at 5:02 AM
Haemonetics Co. (HAE) Sees Significant Increase in Short InterestHaemonetics Co. (HAE) Sees Significant Increase in Short Interest
www.americanbankingnews.com - March 6 at 1:48 AM
WINTON GROUP Ltd Invests $6.26 Million in Haemonetics Co. (HAE) StockWINTON GROUP Ltd Invests $6.26 Million in Haemonetics Co. (HAE) Stock
www.americanbankingnews.com - March 5 at 4:09 PM
Haemonetics (HAE) Stock Rating Upgraded by ValuEngineHaemonetics (HAE) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 4 at 5:35 PM
Teacher Retirement System of Texas Purchases Shares of 18,191 Haemonetics Co. (HAE)Teacher Retirement System of Texas Purchases Shares of 18,191 Haemonetics Co. (HAE)
www.americanbankingnews.com - March 4 at 7:06 AM
Head-To-Head Analysis: Haemonetics (HAE) & ICU Medical (ICUI)Head-To-Head Analysis: Haemonetics (HAE) & ICU Medical (ICUI)
www.americanbankingnews.com - March 2 at 9:24 PM
Bogle Investment Management L P DE Grows Position in Haemonetics Co. (HAE)Bogle Investment Management L P DE Grows Position in Haemonetics Co. (HAE)
www.americanbankingnews.com - March 2 at 5:06 AM
Swiss National Bank Raises Position in Haemonetics Co. (HAE)Swiss National Bank Raises Position in Haemonetics Co. (HAE)
www.americanbankingnews.com - March 1 at 5:42 PM
Systematic Financial Management LP Lowers Position in Haemonetics Co. (HAE)Systematic Financial Management LP Lowers Position in Haemonetics Co. (HAE)
www.americanbankingnews.com - February 27 at 11:28 AM
Smith Asset Management Group LP Takes $3.51 Million Position in Haemonetics Co. (HAE)Smith Asset Management Group LP Takes $3.51 Million Position in Haemonetics Co. (HAE)
www.americanbankingnews.com - February 26 at 3:22 PM
Haemonetics Co. (HAE) Shares Sold by Fuller & Thaler Asset Management Inc.Haemonetics Co. (HAE) Shares Sold by Fuller & Thaler Asset Management Inc.
www.americanbankingnews.com - February 25 at 2:21 PM

SEC Filings

Haemonetics (NYSE:HAE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Haemonetics (NYSE:HAE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Haemonetics (NYSE HAE) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.